GLP1R and Parkinson disease: As the GLP-1 receptor agonist exendin-4 has already shown good neuroprotective effects in a phase II clinical trial in PD patients (Athauda et al., 2017, 2019), it is of great interest to demonstrate that a different peptide hormone from the group of metabolic signaling peptides can show similar neuroprotective properties.